Chiesi Farmaceutici, a family-owned international pharma company, has completed its $1.25 billion acquisition of rare disease-focused biopharma Amryt Pharma (Nasdaq:AMYT). The companies announced the deal in January and projected it would close in the first half of 2023.
Strengthening Chiesi’s global rare disease focusChiesi’s decision to acquire Amryt Pharma is part of a broader trend of increased M&A activity in the pharma sector. In the first few months of 2023, Pfizer, Sanofi, AstraZeneca, and Amgen have also announced significant acquisition plans.
The Chiesi acquisition aims to strengthen Chiesi’s Global Rare Diseases business division. Amryt Pharma’s product portfolio includes three approved commercial products:
Lojuxta/Juxtapid (lomitapide) for treating homozygous familial hypercholesterolemia. This condition involves high levels of low-density lipoprotein cholesterol (LDL-C) in the blood, contributing to premature car…